Innoviva, Inc. (INVA)
19.62
-0.12
(-0.63%)
USD |
NASDAQ |
Jan 23, 11:50
Innoviva Cash from Investing (Quarterly): 18.41M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Amgen, Inc. | -414.00M |
| Eli Lilly & Co. | -2.983B |
| Merck & Co., Inc. | -283.00M |
| Axsome Therapeutics, Inc. | -0.058M |
| Keros Therapeutics, Inc. | -0.132M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 49.73M |
| Cash from Financing (Quarterly) | 10.84M |
| Free Cash Flow | 196.54M |
| Free Cash Flow Per Share (Quarterly) | 0.5721 |
| Free Cash Flow to Equity (Quarterly) | 306.97M |
| Free Cash Flow to Firm (Quarterly) | 52.30M |
| Free Cash Flow Yield | 12.67% |